Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Among authors: stegman k. Med. 2024 Jan 12;5(1):42-61.e23. doi: 10.1016/j.medj.2023.12.004. Epub 2024 Jan 4. Med. 2024. PMID: 38181791 Free article.
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, Stegman K, Ophir S, Cao X, Atanasoff K, Lim R, Mena I, Bouvier NM, Kowdle S, Carreño JM, Rivero-Nava L, Raskin A, Moreno E, Johnson S, Rathnasinghe R, Pai CI, Kehrer T, Cabral EP, Jangra S, Healy L, Singh G, Warang P, Simon V, Sordillo EM, van Bakel H, Liu Y, Sun W, Kerwin L, Teijaro J, Schotsaert M, Krammer F, Bresson D, García-Sastre A, Fu Y, Lee B, Powers C, Moran T, Ji H, Tortorella D, Allen R. Duty JA, et al. Among authors: stegman k. Med. 2022 Oct 14;3(10):705-721.e11. doi: 10.1016/j.medj.2022.08.002. Epub 2022 Aug 8. Med. 2022. PMID: 36044897 Free PMC article.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, Sattler RA, Manning JT, Singh A, Lim R, Healy LD, Johnson S, Paz Cabral E, Li D, Lu L, Ledesma A, Lee D, Richards S, Rivero-Nava L, Li Y, Shen W, Stegman K, Blair B, Urata S, Kishimoto-Urata M, Ko J, Du N, Morais K, Lawrence K, Rivera I, Pai CI, Bresson D, Brunswick M, Zhang Y, Ji H, Paessler S, Allen RD. Cao X, et al. Among authors: stegman k. Sci Rep. 2022 Sep 15;12(1):15517. doi: 10.1038/s41598-022-19780-7. Sci Rep. 2022. PMID: 36109550 Free PMC article.
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants.
Hu Q, Zhao Y, Shaabani N, Lyu X, Powers C, Sun H, Cruz V, Stegman K, Xu J, Fossier A, Huang Y, Ho G, Kao Y, Wang Z, Wang Z, Hu Y, Zheng Y, Kyaw L, Zuluaga C, Wang H, Pei H, Allen R, Xie H, Ji H, Chen R. Hu Q, et al. Among authors: stegman k. Mol Ther Nucleic Acids. 2022 Dec 13;30:465-476. doi: 10.1016/j.omtn.2022.10.021. Epub 2022 Nov 2. Mol Ther Nucleic Acids. 2022. PMID: 36345542 Free PMC article.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Among authors: stegman k. Med. 2024 Feb 9;5(2):169-171. doi: 10.1016/j.medj.2024.01.013. Med. 2024. PMID: 38340710 Free article. No abstract available.
13 results